Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low grade serous ovarian cancer (LGSOC).

Trial Details

NCT ID
NCT06494150
Phase
PHASE2
Sponsor
University of Oklahoma
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • nab-Sirolimus
  • Fulvestrant
Locations (sample)
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Patients must have a histologic confirmed low-grade serous ovarian cancer with clinical evidence of reoccurrence.
  • All patients must have measurable disease as defined by RECIST version 1.1.
  • ECOG Performance status must be 0-1.
  • Adequate bone marrow, hepatic and renal function as defined by the protocol.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →